Status:
COMPLETED
Mechanism of Action and Efficacy of Muraglitazar in Type 2 Diabetes
Lead Sponsor:
Bristol-Myers Squibb
Collaborating Sponsors:
Merck Sharp & Dohme LLC
Conditions:
Diabetes Mellitus, Type 2
Eligibility:
All Genders
18-70 years
Phase:
PHASE3
Brief Summary
The purpose of this study is to learn more about how muraglitazar lowers blood sugar in people with type 2 diabetes. The safety of this treatment will also be studied.
Eligibility Criteria
Inclusion
- Type 2 diabetes;
- Serum triglyceride concentration \< or = 600 mg/dL;
- Body mass index \< or = 37 kg/m2
Exclusion
- Type 1 diabetes;
- History of myocardial infarction (MI), coronary angioplasty, bypass graft(s), valvular disease, unstable angina pectoris, transient ischemic attack (TIA), or cerebrovascular accident (CVA) within 6 months;
- Congestive heart failure (NYHA Class III and IV);
- Uncontrolled hypertension;
- Women of Child Bearing Potential
- History of renal disease, peripheral vascular disease (PVD), pulmonary disease, gastrointestinal disease, active liver disease, or endocrine disease
Key Trial Info
Start Date :
May 1 2004
Trial Type :
INTERVENTIONAL
End Date :
May 1 2006
Estimated Enrollment :
42 Patients enrolled
Trial Details
Trial ID
NCT00094991
Start Date
May 1 2004
End Date
May 1 2006
Last Update
September 14 2010
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Local Institution
San Antonio, Texas, United States, 78229-3900
2
Local Institution
Pisa, Italy